Finance News Network

Interviews

Prior Page Next Page

Primary goal achieved: Immutep reports strong Phase II results in sarcoma trial

26 May 2025 - Strong results in soft tissue sarcoma have capped off a busy quarter of immunotherapy progress

Trim Capital: Asset Allocation Strategy – Issue 002

20 May 2025 - Navigating market headwinds with defensive tilt in 2Q25

How Etherstack is powering global emergency networks

13 May 2025 - Mission-critical communications with global expansion potential.

Volatility as opportunity: VanEck’s smarter beta bets

13 May 2025 - Cameron Cormack, Senior Portfolio Manager at VanEck, on ETF strategy and market outlook

Understanding credit investing with AL Capital

12 May 2025 - Phil Smith, a Director at AL Capital, discusses the company's strategy and focus on capital protection.

BluGlass eyes growth with defence and US laser tech deals

12 May 2025 - Chairman James Walker discusses funding, contracts, and commercial momentum for 2025.

Bringing next-generation batteries to market

23 Apr 2025 - The road to commercialisation: Overcoming funding and regulatory hurdles in battery storage

The road to drug approval: Challenges and strategies

21 Apr 2025 - Navigating the FDA Process and Clinical Trial Hurdles

Property, credit, and long-term value: Inside Capital Prudential’s playbook

16 Apr 2025 - Managing Director Jarrad Haynes shares how the firm is navigating risk, scaling development, and positioning for long-term growth.

Building a battery supply chain that lasts: Lessons from Altech

09 Apr 2025 - Martin Stein discusses the supply chain, environmental, and ethical challenges of lithium-ion batteries and the benefits of Altech’s alternative

Bringing immunotherapies to market: From approval to commercial success

07 Apr 2025 - The Final Steps in Drug Development and Market Access

Beyond lithium: Altech’s alternative battery technology for safer storage

26 Mar 2025 - The pros and cons of lithium and CERENERGY grid storage batteries

Redefining real estate investment

19 Mar 2025 - Michael Fazzini, Sales and Distribution Executive at Capital Prudential, discusses the company's strategy.

How immunotherapy works: Unlocking the power of the immune system

17 Mar 2025 - LAG-3 and the Role of Immune Checkpoints in Cancer Treatment

The future of sustainable energy storage

12 Mar 2025 - The demand for grid storage batteries in Europe

A game-changer in dermatology

12 Mar 2025 - The launch of Sofdra and what's next for Botanix

Botanix: Transforming dermatology

12 Mar 2025 - Sofdra's rollout and the path to $100m revenue

Redefining real estate investment

11 Mar 2025 - Delivering predictable income streams through disicplined development

Immunotherapy and autoimmune diseases: A promising new approach

10 Mar 2025 - Addressing Chronic Conditions with Targeted Treatments

Immutep’s Pipeline: Progress in Immunotherapy and Autoimmune Treatments

10 Mar 2025 - CEO Marc Voigt on Clinical Trials, Regulatory Milestones, and Market Growth

Navigating the Choppy Waters: Garry Crole on Market Greed, Fear, and the Perils of Passive Investing

07 Mar 2025 - Markets, valuations, and volatility: What investors need to know

The advantage of semi-government bonds

04 Mar 2025 - Opportunities for fixed-rate bond investors

Immuno-oncology: Challenges, alternatives, and the future of cancer treatment

03 Mar 2025 - Addressing Unmet Needs in Cancer Care

The future of immunotherapy: A growing market and a revolutionary approach

24 Feb 2025 - Immuno-oncology’s Expanding Role in Cancer Treatment

Investing in mid-scale property

07 Feb 2025 - Capital Prudential's Sam Moore on unlocking property development opportunities.

Prior Page Next Page

Interviews

Primary goal achieved: Immutep reports strong Phase II results in sarcoma trial

Trim Capital: Asset Allocation Strategy – Issue 002

How Etherstack is powering global emergency networks

Volatility as opportunity: VanEck’s smarter beta bets

Understanding credit investing with AL Capital

BluGlass eyes growth with defence and US laser tech deals

Bringing next-generation batteries to market

The road to drug approval: Challenges and strategies

Property, credit, and long-term value: Inside Capital Prudential’s playbook

Building a battery supply chain that lasts: Lessons from Altech

Bringing immunotherapies to market: From approval to commercial success

Beyond lithium: Altech’s alternative battery technology for safer storage

Redefining real estate investment

How immunotherapy works: Unlocking the power of the immune system

The future of sustainable energy storage

A game-changer in dermatology

Botanix: Transforming dermatology

Redefining real estate investment

Immunotherapy and autoimmune diseases: A promising new approach

Immutep’s Pipeline: Progress in Immunotherapy and Autoimmune Treatments

Navigating the Choppy Waters: Garry Crole on Market Greed, Fear, and the Perils of Passive Investing

The advantage of semi-government bonds

Immuno-oncology: Challenges, alternatives, and the future of cancer treatment

The future of immunotherapy: A growing market and a revolutionary approach

Investing in mid-scale property

Categories

Newsletter

Subscribe to our Daily Newsletter?

Daily News